DISPATCHES FROM INTERPHEX

Kemwell Talks Expansion and Approvals in India and the US

Related tags Economics India

At this year’s Interphex, Kemwell Biopharma spoke to Outsourcing-Pharma.com about recent expansions in both India and the US.

Kemwell’s Director of Corporate Development Christian Ahlmark, spoke about the FDA approval at its manufacturing plant in Bangalore, India as well as the biologics facility - also in Bangalore – that recently opened its doors.

Kemwell recently announced 1500 sq ft of analytical lab space had been added​ in response to a contract by a major manufacturer.

However, it is not just India where Kemwell has been expanding. Ahlmark said the company was expanding its “lab footprint”​ on the East Coast in order to offer its current customers formulation development, expertise, analyticals and project management services.

Related news

Show more

Related products

show more

2023 State of Clinical Trial Technology Report

2023 State of Clinical Trial Technology Report

Florence Healthcare | 01-Mar-2023 | Insight Guide

Discover the trends shaping clinical trial technology in 2023, from Site Enablement to eISFs, integrations, and site-sponsor collaboration. This report...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Related suppliers

Follow us

Products

View more

Webinars